Clinical trials: Controlled Hypertension
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Hypertension
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
- Trial name
- NCT00522925
- Testing
- PS433540
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Ligand Pharmaceuticals
Primary Open-angle Glaucoma
PRESERFLO® MicroShunt Extension Study
This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with…
- Trial name
- NCT04333433
- Testing
- PRESERFLO® MicroShunt, Trabeculectomy
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 279 people
- Sponsor
- InnFocus Inc.
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Hypertension
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension.
- Trial name
- NCT00523744
- Testing
- Amlodipine, Olmesartan medoxomil, Amlodipine+valsartan
- Where
- 2 sites in Germany
- Volunteers
- 257 people
- Sponsor
- Novartis
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Hypertension
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
To verify the safety and effectiveness of the renal artery radiofrequency ablation system under the guidance of the three-dimensional cardiac electrophysiological mapping system in the renal denervation of essential hypertension.
- Trial name
- NCT05590871
- Testing
- FlashPoint renal denervation system
- Where
- 27 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Hongdian Medical CO., LTD
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
Hypertension
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage 1 and Stage 2 hypertension of carvedilol…
- Trial name
- NCT00347360
- Testing
- lisinopril, carvedilol controlled release formulation
- Where
- 151 sites in United States
- Volunteers
- 654 people
- Sponsor
- GlaxoSmithKline
Hypertension
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
Patients having uncontrolled or poorly controlled hypertension are at risk of experiencing cardiovascular events such as myocardial infarction or stroke.
- Trial name
- NCT00750113
- Testing
- Nifidipine, Telmisartan, Nifedipine/Telmisartan
- Where
- 43 sites in Italy, Spain
- Volunteers
- 405 people
- Sponsor
- Bayer
Primary Open Angle Glaucoma
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight…
- Trial name
- MAGIC (NCT05786196)
- Testing
- Ab-interno canaloplasty utilizing the iTrack Advance device, Ab-interno canaloplasty utilizing the OMNI Surgical System
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 86 people
- Sponsor
- Nova Eye, Inc.
Subjects With Mild Hypertension
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
- Trial name
- NCT07117474
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hypertension, Pulmonary
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00694850
- Testing
- Riociguat (Adempas, BAY63-2521).
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Bayer
Resistant Hypertension
A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension
Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3…
- Trial name
- NCT07635914
- Testing
- Aprocitentan tablets(SYH9108)
- Volunteers
- 382 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Glaucoma, Open-Angle
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice.
- Trial name
- NCT05710198
- Testing
- Citicoline eye drops 2%
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Omikron Italia S.r.l.
Portal Hypertension
Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications
The objective of this study is to assess the non-inferiority of the intraparenchymal portal vein covered stent in terms of safety and efficacy for managing portal hypertension and its related complications, in comparison to the…
- Trial name
- NCT06320912
- Testing
- The intraparenchymal portal vein covered stent, TIPS Covered Stent System GORE
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Shanghai Shenqi Medical Technology Co., Ltd
Hypertension
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor…
- Trial name
- Darusentan (NCT00389675)
- Testing
- Darusentan, Guanfacine
- Where
- 99 sites in United States, Argentina and 2 more
- Volunteers
- 661 people
- Sponsor
- Gilead Sciences
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
- Trial name
- NCT00770861
- Testing
- Nebivolol
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 277 people
- Sponsor
- Forest Laboratories